Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
Kodiak Sciences Inc (KOD) shares rose over 162% after its experimental drugs, Zenkuda and tabirafusp-ted, met primary endpoints in a phase III trial for wet age-related macular degeneration. Both drugs showed noninferiority to aflibercept in vision gains at one year, with Zenkuda also meeting key secondary endpoints. The company plans to submit a biologics license application for Zenkuda in Q4 2026.
How this was made
The 30-second read
Why it matters
The trial's success positions Kodiak for a biologics license application later this year, potentially expanding its market reach.
Market read
First‑report of pivotal Phase III data for a listed biotech, driving a massive intraday rally and likely influencing sector sentiment.
What to watch
Regulatory review timelines and competitive landscape with existing anti‑VEGF drugs.
Background
Kodiak Sciences (NASDAQ:KOD) focuses on novel biologics for eye diseases. The DAYBREAK trial evaluated two candidates, Zenkuda and tabirafusp‑ted, against aflibercept.
Ticker impact
Kodiak Sciences announced its Phase III DAYBREAK trial met primary endpoints, driving a 162% share surge.
upward pressure as investors price in the successful trial results
First report of pivotal Phase III data for a listed biotech, with a double‑digit same‑day price jump.
Market effects
May boost sentiment for the broader ophthalmology and biotech sectors.
U.S. biotech stocks could see spillover gains.
Positive data could attract international investors to AMD‑related therapies.
Counterpoint
Skeptics may question long‑term commercialization risk and pricing pressure.
Key entities
- companyKodiak Sciences
Biotech firm developing eye‑disease therapies.
- drugZenkuda
Experimental therapy evaluated in the trial.
- drugtabirafusp‑ted
Second experimental therapy evaluated in the trial.
